# US 2026/0083838 A1 · Adjuvant Composition Comprising STING Agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083838 A1
- Document ID: US20260083838A1
- Status: Published application
- Kind: A1
- Application number: 18/702,442
- Filed: 2022-10-17
- Published: 2026-03-26
- Earliest claimed: 2021-10-19
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: GlaxoSmithKline Biologicals SA
- Inventors: Kamelia BEHNIA; Dunja SOBOT; Laurent STRODIOT
- Web page: https://patentgrep.com/patent/US20260083838A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 39/25: Varicella-zoster virus
- A61P 31/22: for herpes viruses
- A61P 37/04: Immunostimulants
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to an adjuvant composition comprising: (i) a STING agonist of Formula (I) or a pharmaceutically acceptable salt thereof and (ii) aluminium hydroxide, aluminium phosphate, aluminium oxyhydroxide, or aluminium hydroxy phosphate; immunogenic compositions comprising the adjuvant composition, their use in methods of immunising a subject, and related aspects thereof.

## Claims

### Claim 1

An adjuvant composition comprising:
(i) a STING agonist of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I) being:
wherein:
X is a -halo(C1-C5)alkyl, an unsubstituted —C1-C5 alkyl, or an unsubstituted —C2-C5 alkenyl;
R1 and R9 are independently H, a halogen, a hydroxyl, —O—P(O)(OH)2, —O—P(O)(R)2, an optionally substituted C1-C6 alkyl, or an optionally substituted C1-C6 alkyloxy,
wherein the optionally substituted C1-C6 alkyl and the optionally substituted C1-C6 alkyloxy are independently optionally substituted with one to four substituents, each independently selected from: a hydroxyl, —O—P(O)(OH)2, —O—P(O)(RI)2, a C1-C4 alkoxyl, a —N(RA)2, a —CO2(RB), an optionally substituted phenyl, and an optionally substituted 5-6 membered heterocycloalkyl,
wherein the optionally substituted phenyl and the optionally substituted 5-6 membered heterocycloalkyl are each optionally substituted by one to four substituents, each independently selected from:
a halogen, a hydroxy, —O—P(O)(OH)2, —O—P(O)(RI)2, an amino, a (C1-C6 alkyl)amino-, a (C1-C6 alkyl)(C1-C6 alkyl)amino-, a halo(C1-C6 alkyl), a hydroxy-(C1-C4 alkyl)-, a —(C1-C4 alkyl)-O—P(O)(OH)2, a —(C1-C4alkyl)-O—P(O)(RI)2, a halo(C1-C4 alkoxy)-, a C1-C4 alkoxy-, a hydroxy-(C2-C4 alkoxy)-, a —(C2-C4 alkoxy)-O—P(O)(OH)2, a —(C2-C4 alkoxy)-O—P(O)(RI)2, a —(C1-C6 alkyl)-NH2, a —C1-C4 alkyl-(C1-C4 alkoxyl), and a C1-C4 alkoxy-(C1-C4 alkoxy)-,
wherein RA and RB are each independently selected from: H, a —C1-C4 alkyl, a —CO(C1-C4 alkyl), a —OCO(C1-C4 alkyl), a —(C1-C4 alkyl)-NH2, a —(C1-C4 alkyl)-C1-C4 alkoxyl, and a —CO2(C1-C4 alkyl),
R2 and R7 are:
(a) each independently H, a —CON(RC)2, —COOH, or a CO2(RD), or
(b) one of R2 and R7 is —CON(RC)(RD) and the other of R2 and R7 is H, —COOH, or CO2(RE), wherein RC and RD are each independently selected from H, a —C1-C4 alkyl, a —CO(C1-C4 alkyl), a —OCO(C1-C4 alkyl), a —(C1-C4 alkyl)-NH2, a —(C1-C4 alkyl)-C1-C4 alkoxyl, or a —CO2(C1-C4 alkyl);
R3 and R8 are each independently H, a halo(C1-C6alkyl), a halo(C1-C6alkoxy)-, a hydroxy, —O—P(O)(OH)2, a —O—P(O)(RI)2, a —NRCRDa —CORC, a —CO2RC, a —N(RD)CORC, a —N(RD)SO2RC, a —N(Rg)SO2(C1-C2alkyl)-N(Rh)(Rf), or a —N(Rg)CO(C1-C2alkyl)-N(Rh)(Rf); wherein Re, Rf, Rg, and Rh are each independently H or a C1-C4 alkyl;
R4, R5, R11, and R12 are each independently H or C1-C4 alkyl; R6 and R10 are each C1-C4 alkyl; and each occurrence of R is independently C1-C6 alkyloxy-; and
(ii) an aluminium salt comprising aluminium hydroxide, aluminium phosphate, aluminium oxyhydroxide, or aluminium hydroxyphosphate.

### Claim 2 (depends on 1)

The adjuvant composition of claim 1, wherein the STING agonist has the structure of Formula (II) or a pharmaceutically acceptable salt thereof; Formula (II) being:
wherein:
X is a -halo(C1-C5)alkyl, an unsubstituted —C1-C5 alkyl, or an unsubstituted —C2-C5 alkenyl;
R1 and R9 are independently H, a halogen, a hydroxyl, —O—P(O)(OH)2, —O—P(O)(R)2, an optionally substituted C1-C6 alkyl, or an optionally substituted C1-C6 alkyloxy,
wherein the optionally substituted C1-C6 alkyl and the optionally substituted C1-C6 alkyloxy are independently optionally substituted with one to four substituents, each independently selected from: a hydroxyl, —O—P(O)(OH)2, —O—P(O)(RI)2, a C1-C4 alkoxyl, a —N(RA)2, a —CO2(RB), an optionally substituted phenyl, and an optionally substituted 5-6 membered heterocycloalkyl,
wherein the optionally substituted phenyl and the optionally substituted 5-6 membered heterocycloalkyl are each optionally substituted by one to four substituents, each independently selected from:
a halogen, a hydroxy, —O—P(O)(OH)2, —O—P(O)(R)2, an amino, a (C1-C6 alkyl)amino-, a (C1-C6 alkyl)(C1-C6 alkyl)amino-, a halo(C1-C6 alkyl), a hydroxy-(C1-C4 alkyl)-, a —(C1-C4 alkyl)-O—P(O)(OH)2, a —(C1-C4alkyl)-O—P(O)(R)2, a halo(C1-C4 alkoxy)-, a C1-C4 alkoxy-, a hydroxy-(C2-C4 alkoxy)-, a —(C2-C4 alkoxy)-O—P(O)(OH)2, a —(C2-C4 alkoxy)-O—P(O)(R)2, a —(C1-C6 alkyl)-NH2, a —C1-C4 alkyl-(C1-C4 alkoxyl), and a C1-C4 alkoxy-(C1-C4 alkoxy)-,
wherein RA and RB are each independently selected from: H, a —C1-C4 alkyl, a —CO(C1-C4 alkyl), a —OCO(C1-C4 alkyl), a —(C1-C4 alkyl)-NH2, a —(C1-C4 alkyl)-C1-C4 alkoxyl, and a —CO2(C1-C4 alkyl),
R5, and R11 are each independently H or C1-C4 alkyl; and
R6 and R10 are each C1-C4 alkyl; and each occurrence of R is independently C1-C6 alkyloxy.

### Claim 3 (depends on 1)

The adjuvant composition of claim 1, wherein:
(i) R1 and R9 are each independently H, the halogen, the optionally substituted (C1-C6alkyl), or the optionally substituted (C1-C6alkyl)oxy-, wherein the C1-C6alkyl of the optionally substituted (C1-C6alkyl) and the C1-C6alkyl of the optionally substituted (C1-C6alkyl)oxy- are each independently optionally substituted with 1-4 substituents, each independently selected from the group consisting of a hydroxyl, —O—P(O)(OH)2, a —O—P(O)(RI)2, —N(Re)(Rf), a C1-C4alkoxyl, a phenyl, an optionally substituted 5-6 membered heterocycloalkyl that contains at least one nitrogen or oxygen as a member of the ring, wherein:
each Re is independently selected from, H, a (C1-C4alkyl), a —(C1-C4alkyl)-NH2, and a —(C1-C4alkyl) C1-C4alkoxy and each Rf is independently H or a (C1-C4alkyl);
(ii) one of R1 and R9 is —O—P(O)(OH)2, a —O—P(O)(RI)2, a C1-C6 alkyl that is substituted with —O—P(O)(OH)2 or —O—P(O)(RI)2, or a C1-C6 alkyloxy group; or
(iii) at least one of R1 and R9 is selected from the following groups:
where a is a number from 2 to 6;
where b is a number from 1 to 6;
where c is a number from 1 to 6;
where d is a number from 1 to 6, and RJ and RK are C1-C3 alkyl; and
where e is a number from 1 to 6, and Q is selected from O or N(RX) wherein RX is a C1-C6 alkyl.

### Claim 4 (depends on 1)

The adjuvant composition of claim 1, wherein the STING agonist is selected from:
(E)-1-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-7-(3-hydroxypropoxy)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide;
4-(((E)-6-carbamoyl-3-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-2,3-dihydro-1H-benzo[d]imidazol-4-yl)oxy)butanoic acid;
(E)-1-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-7-methoxy-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-7-(3-(dimethylamino)propoxy)-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-2,3-dihydro-TH-benzo[d]imidazole-5-carboxamide;
(E)-1-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-TH-pyrazole-5-carbonyl)imino)-7-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propoxy)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-7-methoxy-2,3-dihydro-TH-benzo[d]imidazole-5-carboxamide;
(E)-1-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-TH-pyrazole-5-carbonyl)imino)-7-(3-hydroxypropoxy)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-TH-pyrazole-5-carbonyl)imino)-7-methoxy-2,3-dihydro-TH-benzo[d]imidazole-5-carboxamide;
(E)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazole-5-carboxamide;
(E)-1-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-TH-pyrazole-5-carbonyl)imino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-TH-pyrazole-5-carbonyl)imino)-7-(3-morpholinopropoxy)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide;
(E)-1-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-7-(3-morpholinopropoxy)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-7-methoxy-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide;
3-(((E)-6-carbamoyl-3-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-TH-pyrazole-5-carbonyl)imino)-7-methoxy-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-TH-pyrazole-5-carbonyl)imino)-2,3-dihydro-1H-benzo[d]imidazol-4-yl)oxy)propyl dihydrogen phosphate; and
a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The adjuvant composition of claim 1, wherein the STING agonist is:
(3-(((E-6-carbamoyl-3-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-7-methoxy-2,3-dihydro-TH-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-2,3-dihydro-1H-benzo[d]imidazol-4-yl)oxy)propyl dihydrogen phosphate).

### Claim 6 (depends on 1)

The adjuvant composition of claim 1 comprising the aluminium hydroxide.

### Claim 7 (depends on 6)

The adjuvant composition of claim 6, wherein the STING agonist is adsorbed on the aluminium hydroxide.

### Claim 8 (depends on 6)

The adjuvant composition of claim 6 comprising: from 50 μg to 500 μg of the aluminium hydroxide per dose of the adjuvant composition or from 0.5 μg to 250 μg of the STING agonist per dose of the adjuvant composition.

### Claim 9 (depends on 1)

An immunogenic composition comprising:
(i) the adjuvant composition of claim 1 and
(ii) an antigen.

### Claim 10 (depends on 9)

The immunogenic composition according to claim 9,
wherein the antigen is a cancer cell antigen or
a human pathogen antigen;
the human pathogen antigen optionally being selected from: a bacteria antigen, a virus antigen, a fungus antigen, a parasitic microorganism antigen, and a multicellular parasite antigen.

### Claim 11 (depends on 10)

The immunogenic composition of claim 10, wherein the antigen is the human pathogen antigen, and the human pathogen antigen is selected from: a coronavirus antigen, a herpes simplex virus (HSV) a en, a human immunodeficiency virus (HIV) antigen, a hepatitis B virus antigen, a hepatitis C virus antigen, a meningitis B virus antigen, a Haemophilus influenzae type B bacteria antigen, a Bordetella pertussis bacteria antigen, a diphtheria bacteria antigen, a tetanus bacteria antigen, influenza virus antigen, respiratory syncytial virus (RSV) antigen, a human papillomavirus (HPV) antigen, a measles virus antigen, a rubella virus antigen, a mumps virus antigen, human cytomegalovirus (HCMV) antigen, a varicella zoster virus (VZV) antigen, a Dengue virus antigen, a poliovirus antigen, an Ebola virus antigen, a rotavirus antigen, and any combination of two or more thereof.

### Claim 12 (depends on 11)

The immunogenic composition of claim 11, wherein the antigen is: a VZV antigen, an HSV antigen, or an HSV-2 gE-gI antigen.

### Claim 13 (depends on 9)

The immunogenic composition of claim 9, wherein the adjuvant composition comprises the aluminium hydroxide and the antigen is adsorbed on the aluminium hydroxide.

### Claim 14 (depends on 1)

A method of immunizing a host comprising administering to the host an adjuvant composition of claim 1 and an antigen, optionally wherein the antigen is: (i) formulated in a separate composition to the adjuvant composition and (ii) administered separately.

### Claim 15 (depends on 1)

A kit comprising:
i) a first container comprising the adjuvant composition of claim 1 and
ii) a second container comprising an antigen.

### Claim 16 (depends on 9)

A method of immunizing a host comprising administering to the host an immunogenic composition of claim 9.

### Claim 17 (depends on 8)

The adjuvant composition of claim 8 comprising: the from 50 μg to 500 μg of the aluminium hydroxide per dose of the adjuvant composition and the from 0.5 μg to 250 μg of the STING agonist per dose of the adjuvant composition.

### Claim 18 (depends on 1)

The adjuvant composition of claim 1, the aluminium salt comprising aluminium hydroxide and aluminium phosphate.
